News
Clinical Topics
Integrative Care
Global Bulletin
All News
Approval Alert
Media
2 Minute Drill
Around the Practice
Between the Lines
Clinical Consult
Expert Interviews
Face Off
Medical World News
Morning Rounds
OncView
Podcasts
Readout 360
Satellite Sessions
Sponsored Media
Training Academy
Year in Review
Conferences
Publications
All Journals
For Authors
Tumor Board
Events
Frontline Forum
CME/CE
Resources
Contemporary Concepts
Awareness Month
Interactive Tools
Nurse Practitioners/Physician's Assistants
Partners
Sponsored
Subscribe
Print Subscription
eNewsletter

logo
Spotlight
Around the Practice
Between the Lines
Contemporary Concepts
Journal
OncView
Podcasts
Readout 360
2022 ASCO Genitourinary Cancers Symposium Urothelial Cancer Updates
CancerNetwork® Inaugural Face-Off
Contemporary Concepts in Hematologic Oncology
Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice
Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer
Clinical
Acute Myeloid Leukemia
Brain Cancer
Breast Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Gynecologic Cancer
Hematology
Leukemia
Lung Cancer
Lymphoma
Pediatric Cancers
Skin Cancer
Clinical Topics
Integrative Care
Global Bulletin
All News
Approval Alert
2 Minute Drill
Around the Practice
Between the Lines
Clinical Consult
Expert Interviews
Face Off
Medical World News
Morning Rounds
OncView
Podcasts
Readout 360
Satellite Sessions
Sponsored Media
Training Academy
Year in Review
Conferences
All Journals
For Authors
Tumor Board
Frontline Forum
CME/CE
Contemporary Concepts
Awareness Month
Interactive Tools
Nurse Practitioners/Physician's Assistants
Partners
Sponsored
Print Subscription
eNewsletter
Advertisement
Breast Cancer
| Kidney Cancer
| Leukemia
| Lymphoma
| Multiple Myeloma
| Non-Small Cell Lung Cancer (NSCLC)
| Small Cell Lung Cancer (SCLC)
| Adverse Effects
| Biomarkers
| Bladder Cancer
| Brain Cancer
| Cervical Cancer
| Colorectal Cancer
| Endometrial Cancer
| Esophageal Cancer
| Gastrointestinal Cancer
| Genitourinary Cancers
| Gynecologic Cancers
| Head & Neck Cancer
| Hematology
| Hormone-related Cancers
| Immunotherapy
| Infection
| Liver Cancer
| Lung Cancer
| Mesothelioma
| Neuroendocrine Tumors
| Oncology
| Ovarian Cancer
| Ovarian Cancer Clincal Consult
| Pancreatic Cancer
| Pediatric Cancers
| Prostate Cancer
| Radiation Oncology
| Sarcoma
| Screening
| Skin Cancer & Melanoma
| Surgery
| Thoracic Malignancies
| Thyroid Cancer
View All >>
  • Adverse Effects
  • Biomarkers
  • Bladder Cancer
  • Brain Cancer
  • Breast Cancer
  • Cervical Cancer
  • Colorectal Cancer
  • Endometrial Cancer
  • Esophageal Cancer
  • Gastrointestinal Cancer
  • Genitourinary Cancers
  • Gynecologic Cancers
  • Head & Neck Cancer
  • Hematology
  • Hormone-related Cancers
  • Immunotherapy
  • Infection
  • Kidney Cancer
  • Leukemia
  • Liver Cancer
  • Lung Cancer
  • Lymphoma
  • Mesothelioma
  • Multiple Myeloma
  • Neuroendocrine Tumors
  • Non-Small Cell Lung Cancer (NSCLC)
  • Oncology
  • Ovarian Cancer
  • Ovarian Cancer Clincal Consult
  • Pancreatic Cancer
  • Pediatric Cancers
  • Prostate Cancer
  • Radiation Oncology
  • Sarcoma
  • Screening
  • Skin Cancer & Melanoma
  • Small Cell Lung Cancer (SCLC)
  • Surgery
  • Thoracic Malignancies
  • Thyroid Cancer

SPOTLIGHT -

Around the Practice
| Between the Lines
| Contemporary Concepts
| Journal
| OncView
| Podcasts
| Readout 360
| 2022 ASCO Genitourinary Cancers Symposium Urothelial Cancer Updates
| CancerNetwork® Inaugural Face-Off
| Contemporary Concepts in Hematologic Oncology
| Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice
| Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer

FDA Approves Zoledronic Acid for Cancer-Related Bone Complications

Apr 1, 2002
OncologyONCOLOGY Vol 16 No 4
Volume 16
Issue 4

The US Food and Drug Administration (FDA) has approved zoledronic acid (Zometa) for the treatment of bone complications in patients with multiple myeloma and patients with solid tumors, in conjunction with standard antineoplastic therapy.

The US Food and Drug Administration (FDA)has approved zoledronic acid (Zometa) for the treatment of bone complications inpatients with multiple myeloma and patients with solid tumors, in conjunctionwith standard antineoplastic therapy. These solid tumors include prostatecancer, lung cancer, and breast cancer. Prostate cancer patients should haveprogressed after completing treatment with at least one hormonal therapy.

"At Novartis, we are committed to developing innovative andpractical new treatments for patients with cancer," said David Epstein,president, Novartis Oncology. "With this approval, Zometa offers tophysicians and patients a new, broadly effective and convenient treatment forthe debilitating bone complications of cancer."

Three Large Trials

The approval of zoledronic acid is based on data from threelarge international clinical investigations that evaluated more than 3,000patients with prostate cancer, lung cancer, breast cancer, other solid tumors,and multiple myeloma. These clinical trials demonstrated that zoledronic aciddecreases the skeletal complications in patients with multiple myeloma and withmetastases from solid tumors.

In two placebo-controlled clinical studies conducted in patientswith bone metastases from prostate cancer or from other solid tumors, the numberof patients with skeletal events decreased and the time to firstskeletal-related event increased with zoledronic acid treatment, in comparisonwith placebo.

Unmet Clinical Need

"Advanced cancers commonly spread to bone and cause avariety of complications that can significantly impact a patient’s day-to-dayactivities," said Matthew Smith, MD, PhD, assistant professor of medicineat Harvard Medical School and Massachusetts General Hospital, Boston."There’s an unmet clinical need to address these complications,especially in patients with prostate cancer, which makes Zometa an importantaddition to the current standard treatments for men with advanced prostatecancer."

Safety Considerations

Zoledronic acid and other bisphosphonates have been associatedwith renal insufficiency. Patients should have serum creatinine levels assessedprior to receiving each dose of zoledronic acid. Caution is advised whenadministering zoledronic acid with other potentially nephrotoxic drugs. Doses ofthe agent should not exceed 4 mg, and the duration of infusion should be no lessthan 15 minutes.

Zoledronic acid was generally well tolerated, with a safetyprofile similar to that of other bisphosphonates. The most commonly reportedadverse events included a flu-like syndrome (fever, arthralgias, myalgias,skeletal pain), fatigue, gastrointestinal reactions, anemia, weakness, cough,dyspnea, and edema. Occasionally, patients experienced electrolyte and mineraldisturbances, such as low serum phosphate, calcium, magnesium, and potassium.

Articles in this issue

Introduction to Irinotecan and Other Agents in Colorectal Cancer, Volume 1
Deputy Director Named for FDA’s Division of Oncology Drug Products
InTouch and ASCO Announce New Cancer Information Feature
Optimized Strategy for Lymph Node Analysis Studied
Clinical Oncology: A Multidisciplinary Approach for Physicians and Students, 8th Edition
First Radioimmunotherapy Approved by FDA
Major Cancer Bill Introduced in Senate
FDA Approves Zoledronic Acid for Cancer-Related Bone Complications
Recurrent Ovarian Cancer as Chronic Disease
Current Clinical Trials of Molecularly Targeted Agents in Children With Cancer, Part 2
Irinotecan Therapy for Small-Cell Lung Cancer
Update on European Adjuvant Trials With Irinotecan for Colorectal Cancer
Changing Perspectives on Palliative Care
The Role of Mitoxantrone in Non-Hodgkin’s Lymphoma
Changing Perspectives on Palliative Care
Related Videos
Experts on MM
Experts on MM
An expert from Vanderbilt University Medical Center says that patients with relapsed/refractory multiple myeloma may be able to live a normal life following response to salvage treatment with bispecific monoclonal antibodies.
Experts on multiple myeloma
Experts on multiple myeloma
Expert on MM
Experts on multiple myeloma
Experts on multiple myeloma
Related Content

Novel CAR T Therapy Yields Safety, Responses in R/R Multiple Myeloma

June 4th 2023

Oncology On-The-Go Podcast: Multiple Myeloma Outcome Disparities, Trial Access

April 12th 2023

Talquetamab/Daratumumab Garners Robust Response Rate in R/R Myeloma

June 4th 2023

Between the Lines™ Podcast: Updates in Use of Proteasome Inhibitors for Relapsed/Refractory Multiple Myeloma

May 23rd 2022

Investigators Report Efficacy Trends With PHE885 in R/R Multiple Myeloma

June 4th 2023

Teclistamab/Talquetamab Appears Tolerable in R/R Multiple Myeloma

June 3rd 2023

Novel CAR T Therapy Yields Safety, Responses in R/R Multiple Myeloma

June 4th 2023

Oncology On-The-Go Podcast: Multiple Myeloma Outcome Disparities, Trial Access

April 12th 2023

Talquetamab/Daratumumab Garners Robust Response Rate in R/R Myeloma

June 4th 2023

Between the Lines™ Podcast: Updates in Use of Proteasome Inhibitors for Relapsed/Refractory Multiple Myeloma

May 23rd 2022

Investigators Report Efficacy Trends With PHE885 in R/R Multiple Myeloma

June 4th 2023

Teclistamab/Talquetamab Appears Tolerable in R/R Multiple Myeloma

June 3rd 2023

Novel CAR T Therapy Yields Safety, Responses in R/R Multiple Myeloma

June 4th 2023

Oncology On-The-Go Podcast: Multiple Myeloma Outcome Disparities, Trial Access

April 12th 2023

Talquetamab/Daratumumab Garners Robust Response Rate in R/R Myeloma

June 4th 2023

Between the Lines™ Podcast: Updates in Use of Proteasome Inhibitors for Relapsed/Refractory Multiple Myeloma

May 23rd 2022

Investigators Report Efficacy Trends With PHE885 in R/R Multiple Myeloma

June 4th 2023

Teclistamab/Talquetamab Appears Tolerable in R/R Multiple Myeloma

June 3rd 2023
Related Content

Novel CAR T Therapy Yields Safety, Responses in R/R Multiple Myeloma | Image Credit: © LASZLO - stock.adobe.com.

Novel CAR T Therapy Yields Safety, Responses in R/R Multiple Myeloma

June 4th 2023
Article

GCF012F may show promising activity in relapsed and refractory multiple myeloma, according to an expert from Shanghai Chang Zheng Hospital.


Krina Patel, MD, MSc, discusses research and initiatives that may help to mitigate disparities in patients with multiple myeloma including factors such as gender, race, and ethnicity.

Oncology On-The-Go Podcast: Multiple Myeloma Outcome Disparities, Trial Access

April 12th 2023
Podcast

Krina Patel, MD, MSc, discusses research and initiatives that may help to mitigate disparities in patients with multiple myeloma including factors such as gender, race, and ethnicity.


Numerous patients with heavily pretreated relapsed/refractory multiple myeloma responded following treatment with talquetamab and daratumumab.

Talquetamab/Daratumumab Garners Robust Response Rate in R/R Myeloma

June 4th 2023
Article

Numerous patients with heavily pretreated relapsed/refractory multiple myeloma responded following treatment with talquetamab and daratumumab.


Paul G. Richardson, MD, and Christina Gasparetto, MD, offer insights into the use of proteasome inhibitors in relapsed or refractory multiple myeloma.

Between the Lines™ Podcast: Updates in Use of Proteasome Inhibitors for Relapsed/Refractory Multiple Myeloma

May 23rd 2022
Podcast

Paul G. Richardson, MD, and Christina Gasparetto, MD, offer insights into the use of proteasome inhibitors in relapsed or refractory multiple myeloma.


Investigators Report Efficacy Trends With PHE885 in R/R Multiple Myeloma

Investigators Report Efficacy Trends With PHE885 in R/R Multiple Myeloma

June 4th 2023
Article

A phase 1 trial continued to show positive responses when PHE885 was used in patients with relapsed/refractory multiple myeloma.


Teclistamab/Talquetamab Appears Tolerable in R/R Multiple Myeloma

Teclistamab/Talquetamab Appears Tolerable in R/R Multiple Myeloma

June 3rd 2023
Article

Results from the phase 1b RedirecTT-1 study show acceptable efficacy and safety when teclistamab plus talquetamab was given to patients with relapsed/refractory multiple myeloma.

About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.